16 October 2026 Dear Shareholder Cynata Therapeutics Limited – Pro-Rata Renounceable Entitlement O<er As announced on 8 October 2026, Cynata Therapeutics Limited (ACN 104 037 372) (CYP or the Company), is undertaking a pro-rata renounceable entitlement oIer in accordance with the terms of the entitlement oIer prospectus (Prospectus) lodged with ASIC and ASX on 12 October 2026. The Prospectus replaced the original prospectus lodged with ASIC and ASX on 8 October 2026. Other than as defined in this letter, capitalised terms have the meanings given to them in the Prospectus. The Entitlement OIer, which is fully underwritten by Caravel Securities Pty Ltd, aims to raise approximately $913,000 (before costs) and has the following terms: 1. The Entitlement OIer is renounceable and pro-rata to Eligible Shareholders on the basis of three (3) fully paid ordinary shares in the capital of the Company (New Shares) for every eight (8) Shares held by those Shareholders at the Record Date of 13 October 2026 at an OIer Price of $0.01 per New Share. 2. For every three (3) New Shares subscribed for under the Entitlement OIer, Eligible Shareholders will receive one free attaching option (Option), on the following terms: a. Option exercise price of $0.02; and b. Option expiry date 2.5 years after the date of issue. The funds raised from the Entitlement OIer will be used to pay for professional advisers, Director and consultant fees in furtherance of the Company’s strategic objectives and to pay for the costs of the OIers and for working capital purposes. Ineligible Shareholders Any Cynata Shareholder who has a registered address outside of Australia, New Zealand and Singapore (Ineligible Shareholder) will not be eligible to participate in the Entitlement OIer. Our records indicate that you are an Ineligible Shareholder, You are not eligible to participate in the OIer, and you will not be sent a copy of the Prospectus. This decision has been made pursuant to ASX Listing Rule 7.7.1(a) after taking into consideration the costs of complying with legal and regulatory requirements in jurisdictions outside of Australia, New Zealand and Singapore compared with the small number of Ineligible Shareholders and the number and value of Shares to which they would otherwise be entitled. Thank you for your support of Cynata. Yours sincerely Dr GeoIrey Brooke Non-Executive Chair